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Endoglin Regulates Cyclooxygenase-2 Expression
and Activity
Mirjana Jerkic, Juan V. Rivas-Elena, Juan F. Santibanez, Marta Prieto, Alicia Rodrı´guez-Barbero,
Fernando Perez-Barriocanal, Miguel Pericacho, Miguel Are´valo, Calvin P.H. Vary, Michelle Letarte,
Carmelo Bernabeu, Jose M. Lo´pez-Novoa
Abstract—The endoglin heterozygous (Eng/) mouse, which serves as a model of hereditary hemorrhagic telangiectasia
(HHT), was shown to express reduced levels of endothelial NO synthase (eNOS) with impaired activity. Because of
intricate changes in vasomotor function in the Eng/ mice and the potential interactions between the NO- and
prostaglandin-producing pathways, we assessed the expression and function of cyclooxygenase (COX) isoforms. A
specific upregulation of COX-2 in the vascular endothelium and increased urinary excretion of prostaglandin E2 were
observed in the Eng/ mice. Specific COX-2 inhibition with parecoxib transiently increased arterial pressure in Eng/
but not in Eng/ mice. Transfection of endoglin in L6E9 myoblasts, shown previously to stimulate eNOS expression,
led to downregulation of COX-2 with no change in COX-1. In addition, COX-2 promoter activity and protein levels
were inversely correlated with endoglin levels, in doxycyclin-inducible endothelial cells. Chronic NO synthesis
inhibition with N-nitro-L-arginine methyl ester induced a marked increase in COX-2 only in the normal Eng/ mice.
N-nitro-L-arginine methyl ester also increased COX-2 expression and promoter activity in doxycyclin-inducible
endoglin expressing endothelial cells, but not in control cells. The level of COX-2 expression following transforming
growth factor-1 treatment was less in endoglin than in mock transfected L6E9 myoblasts and was higher in human
endothelial cells silenced for endoglin expression. Our results indicate that endoglin is involved in the regulation of
COX-2 activity. Furthermore, reduced endoglin levels and associated impaired NO production may be responsible, at
least in part, for augmented COX-2 expression and activity in the Eng/ mice. (Circ Res. 2006;99:248-256.)
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Endoglin (CD105) is a homodimeric membrane glycoproteinthat, in association with transforming growth factor
(TGF)- family receptors, binds TGF-1, TGF-3, activin,
bone morphogenetic protein (BMP)-2, and BMP-7.1 Endoglin is
constitutively expressed on endothelial cells of capillaries, veins,
and arteries2,3 and can also be observed, albeit at lower levels, in
contractile cells such as vascular smooth muscle cells,4 and
mesangial cells.5 Mutations in the endoglin (ENG) gene cause
hereditary hemorrhagic telangiectasia type 1 (HHT1), also
known as Rendu–Osler–Weber syndrome.6 HHT is an autoso-
mal dominant vascular dysplasia that affects 1:10 000 individu-
als. This disorder is associated with epistaxis and telangiectases
in the majority of patients and with pulmonary and cerebral
arteriovenous malformations that are more frequent, particularly
in HHT1 patients. ENG mutations are distributed throughout the
gene and lead to haploinsufficiency,7 indicating that endoglin
levels are critical in maintaining vascular homeostasis. Endoglin
null (Eng/) mice die at midgestation of vascular and cardiac
defects, demonstrating the critical role of endoglin in cardiovas-
cular development.8,9,10
The vascular endothelium secretes vasodilators including
NO, which is produced mostly by endothelial NO synthase
(eNOS), and the prostacyclin (PGI2) and prostaglandin E2
(PGE2), which are produced by cyclooxygenases (COXs).11
Endoglin is a regulatory component of the TGF- receptor
system in endothelial cells capable of modulating specific
responses to this multipotent growth factor.10,12,13 Its reduced
expression may result in disruption of the delicate balance in
the secretion of endothelium-derived vasodilators and vaso-
constrictors, thus inducing changes in vascular tone regula-
tion. We have previously demonstrated that endoglin haplo-
insufficiency leads to a complex modification in the
regulation of vascular resistance associated with a decrease in
eNOS expression and impaired activity in Eng/ mice.14,15
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Molecular cross-talk between NOS and COX pathways has
been documented in several cell types including endothelial
cells.16 However, most studies have focused on inflammatory
cells and pharmacological manipulation of both pathways.
Therefore, the mechanisms regulating the production, release,
and fine balance of NO and prostaglandins (PGs) in endothe-
lial cells are still poorly understood. There are reports of
stimulation of PGs by NO in human microvascular and
umbilical vein endothelial cells that suggest an additional
pathway used by nitrovasodilators to elicit vasodilation.16
However, chronic inhibition of NO synthesis by N-nitro-L-
arginine methyl ester (L-NAME) treatment of rats leads to a
decreased flow-induced dilatation in resistance mesenteric
arteries, compensated by an increase in COX-2 expression
and vasodilatory PGs.17,18 NO stimulates PGE2 release in
COX-2–deficient cells, but inhibits such release in COX-1
null cells. The inhibition of COX-2 activity is mediated by
nitration of this enzyme in tyrosine residues.19 It was also
reported that the diverse effects of NO on COX-2 expression
can be: (1) mediated directly or via other stimuli20,21; (2)
related to the cell type and state of activation22; and (3)
dependent on NO concentration, being stimulatory at low
levels and inhibitory at high levels.23
In the current study, we measured COX isoforms expres-
sion and activity in tissues and endothelial cells isolated from
Eng/ mice and identified an inverse relationship between
endoglin and COX-2 levels. We assessed the effect of NOS
and COX-2 inhibition on arterial pressure in Eng/ and
Eng/ mice. We also tested the effects of L-NAME on
COX-2 expression and activity by chronic in vivo adminis-
tration in the murine model of HHT or by in vitro treatment
of cells expressing various levels of endoglin. Our data
indicate that Eng/ mice, shown previously to have impaired
eNOS activity, had elevated COX-2, suggesting that endoglin
plays a role in the maintenance of vascular homeostasis and
the fine balance between eNOS and COX-2 in endothelial
cells.
Materials and Methods
An expanded materials and methods section is available in the online
data supplement at http://circres.ahajournals.org.
Mice
Generation and genotyping of Eng/ mice on a C57BL/6 back-
ground was previously described.8,24 Mice were kept in ventilated
rooms in a germ-free facility. All studies were performed in parallel
in Eng/ and Eng/ littermate female mice aged 4 to 6 months (20
to 25 g). All animal procedures were approved by the University of
Salamanca Animal Care and Use Committee. To inhibit NO synthe-
sis in vivo, L-NAME (Sigma) was administered at a dose of 10
mg/kg per day in the drinking water for 28 days.
Blood Pressure Measurements
Changes in mean arterial pressure (MAP) in response to vasoactive
substances were measured in Eng/ and Eng/ mice as described.14
Mice were treated with the nonselective COX inhibitor indomethacin
(Sigma, I-7378; 5 mg/kg b.m. SC) for 1 hour, the selective COX-2
inhibitor parecoxib (Dynastat, Pharmacia EEIG, Buckinghamshire,
UK; 40 mg/kg b.m. IV) for 30 minutes, or the NO synthesis inhibitor
L-NAME (50 mg/kg body mass IV) for 1 hour. Subsequent com-
bined treatments were given as indicated.
Biological Samples, Tissues, and Aortic
Endothelial Cell Preparation
Urine PGE2 was measured using a high-sensitivity immunoassay
(R&D Systems), and creatinine was quantified using the Jaffe
method. Plasma and urine concentrations of nitrites were determined
by a modification of the Griess method.14 Mice were deeply
anesthetized using isoflurane (Forane, Abbott). The kidneys, lungs,
and femoral arteries were removed, frozen in liquid nitrogen,
individually ground into a fine powder, and stored at 80°C until
used for protein and total RNA extraction. Mouse aortic endothelial
cells (MAECs) from Eng/ and Eng/ mice were isolated and
cultured as described.14
Cell Culture and Transfections
The rat myoblast cell line L6E9 and the doxycycline-inducible
bovine endothelial GM7372-EL cell line25 were cultured in DMEM,
and the human microvascular endothelial (HMEC)-1 cells,26 were
grown in eosin/methylene blue medium (Gibco). The generation of
doxycyclin-inducible endoglin-expressing GM7372-EL cells and
stable rat myoblast transfectants expressing human L-endoglin was
previously described.25,27 The myoblast transfectants were usually
cultured in the presence of 400 g/mL of the G418 antibiotic.
COX-2 transcriptional activity was measured using luciferase re-
porter gene assays28 and was expressed as relative luciferase units
(RLU). To analyze the effect of TGF-1 on COX-2 expression,
L6E9 myoblasts were incubated with different concentrations of
recombinant human TGF-1 (0 to 500 pM) for 24 hours before
Western blot analysis. For RNA interference studies, the human
endothelial cell line HMEC-1 was transiently transfected with the
pXP2–COX-2 luc reporter vector28 and pSUPER-Endo/Ex4 plas-
mid,29 encoding an endoglin-specific sequence of small interference
RNA (siRNA), or pSUPER-C plasmid,29 used as negative control.
After incubation for 36 hours, 400 pM TGF-1 was added, and the
cells were incubated for 24 hours before measurement of the
transcriptional activity.
Western and Northern Blot Analyses
Preparation of tissue and cell extracts for Western blot analysis was
described.5,30 For Northern blot analysis, total RNA was isolated
from tissues using the guanidinium thiocyanate–phenol–chloroform
method and processed as described.14 A 4.5-kb fragment of mouse
COX-2 cDNA (kindly given by Dr Santiago Lamas, Centro Nacional
de Investigaciones Cardiovasculares, Madrid, Spain) was used as
probe. The 28S ribosomal subunit probe (0.7 kb) served as an
internal control.
Results
COX Expression in Endoglin Heterozygous Mice
We first examined the expression of COX-1 and COX-2 in
tissues of mice by Western blot analysis. No difference in
COX-1 protein expression was observed between the Eng/
and Eng/ kidneys (Figure 1A), isolated femoral arteries
(supplemental Figure I), or lung tissues (data not shown).
However, expression of COX-2 protein was higher in kidneys
(2-fold; Figure 1A), femoral arteries (2.6-fold; Figure I),
and lungs (1.8-fold; data not shown) of Eng/ mice
compared with control Eng/ mice. The rise in COX-2
expression was associated with increased biological activity
as confirmed by elevated urinary excretion of PGE2 in Eng/
mice (Figure 1B). Expression of COX-2 mRNA was higher in
renal and pulmonary tissues of Eng/ mice when compared
with control Eng/ mice (2.2- and 2.1-fold, respectively;
Figure 1C).
Immunohistochemical analysis of femoral artery sections
revealed that COX-2 is expressed mainly in endothelial cells
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but also in scattered smooth muscle cells in both Eng/ and
Eng/ mice (Figure 2A and 2B). The cellular staining was
specific as demonstrated by the lack of reactivity of the
nonimmune serum (Figure 2C). The expression of COX-2
was higher in femoral arteries of Eng/ mice, in agreement
with the elevated levels of COX-2 observed in kidneys and
lungs.
COX-2 Expression Is Increased in Endothelial
Cells Isolated From Endoglin Heterozygous Mice
To confirm the selective increase in COX-2 expression in
endothelial cells of Eng/ mice, we prepared primary cul-
tures of MAECs. As expected for engineered heterozygous
mice, Eng/ MAECs had lower endoglin levels than Eng/
cells (Figure 3A). COX-1 expression was unchanged,
whereas COX-2 expression was increased by 3-fold in aortic
Figure 1. Expression and activity of COX-1 and COX-2 in
Eng/ and Eng/ mice. A, Western blot analysis of renal tis-
sues with antibodies specific for COX-1, COX-2, or -tubulin
(loading control). Densitometry results are expressed as COX/
tubulin ratios. B, Urinary PGE2 excretion was measured by
ELISA and expressed in ng/mg creatinine. C, Northern blot anal-
ysis of kidney and lung total RNA; COX-2 mRNA levels are
expressed relative to the 28S RNA band. Data shown in each
panel are meanSEM of 8 mice per group. *P0.05 vs Eng/
group (Student t test).
Figure 2. COX-2 immunostaining in arteries of Eng/ and
Eng/ mice. Femoral arteries from Eng/ (A) and Eng/ (B)
mice were stained for COX-2. Positive staining was observed in
endothelial cells (arrows) and smooth muscle cells (asterisks).
No staining was seen with a non-immune rabbit serum control
(C). Bar: 100 m.
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endothelial cells from Eng/ mice (Figure 3A). These results
indicate that endothelial cells are at least in part responsible
for the higher COX-2 expression and activity observed in
Eng/ mice.
COX-2 Expression Is Decreased in Endoglin
Transfected L6E9 Myoblasts
To determine whether the increase in COX-2 observed in the
Eng/ mice was related to reduced endoglin levels, we
assessed COX-2 expression in mock-transfected and human
endoglin-transfected L6E9 myoblast cell lines. Figure 3B
illustrates the efficiency of transfection in terms of endoglin
expression and reveals no changes in COX-1 levels. How-
ever, the endoglin-transfected myoblasts showed much re-
duced COX-2 expression relative to the mock-transfected
cells. Thus, the inverse correlation between COX-2 and
endoglin levels, seen in endothelial cells from the HHT
murine model, was reproduced in endoglin transfected
myoblasts.
COX-2 Expression Is Inversely Correlated With
Endoglin Expression in GM7372-EL Cells
To substantiate the potential modulation by endoglin of
COX-2 expression in endothelial cells, a tetracycline-
inducible bovine endothelial cell line, GM7372-EL, was
used.25 These cells have been engineered to express human
endoglin when treated with doxycycline (Dox). Figure 4A
shows that the level of endoglin measured by Western blot
was proportional to the dose of Dox used. Interestingly, the
increase in endoglin was accompanied by a parallel decrease
in COX-2 and increase in eNOS expression levels (Figure
4A). We next analyzed the COX-2 promoter-driven transcrip-
tion in transiently transfected GM7372-EL endothelial cells.
Induction of endoglin expression with increasing concentra-
tions of Dox resulted in a marked inhibition of COX-2
transactivity (Figure 4B).
Chronic NOS Inhibition Leads to Increased
COX-2 Levels in Eng/ But Not in Eng/ Mice
To assess whether lower eNOS expression in Eng/ mice14,15
is responsible for the decreased COX-2 activity, we tested the
effect of chronic NOS inhibition by treating mice with
L-NAME for 28 days. The effectiveness of chronic NO
synthesis inhibition was demonstrated by a decrease in
plasma nitrite concentration in Eng/ mice (from
2.820.48 mol/L in untreated mice to 0.770.20 mol/L
after treatment with L-NAME, P0.01) and in Eng/ mice
(from 1.670.24 mol/L in untreated mice to
0.900.20 mol/L after L-NAME, P0.05).
Western blot analysis showed that COX-2 expression in
kidneys (Figure 5A) and lungs (Figure 5B) of Eng/ mice
was higher in the L-NAME–treated group, suggesting that
NOS inhibition is associated with an increase in COX-2. In
Eng/ mice, which show higher basal levels of COX-2 than
the Eng/ mice, no further increase was obtained by chronic
treatment with L-NAME. Hence, the COX-2 level in Eng/
mice chronically treated with L-NAME was equivalent to the
basal level observed in Eng/ mice. Urinary PGE2 excretion
was also measured after chronic L-NAME treatment, as an
indicator of COX-2 activity. PGE2 excretion in Eng/ mice
was higher in the L-NAME–treated (7.20.6 ng/mg of
creatinine) than untreated (4.20.2 ng/mg of creatinine;
P0.005) group. Basal PGE2 excretion in untreated Eng/
mice (6.40.6 ng/ mg of creatinine) was higher than in
Eng/ mice, as shown in Figure 1B, and these levels were
not increased by chronic treatment with L-NAME (7.40.6
ng/ mg of creatinine; P0.1).
Effect of NO on Endoglin-Dependent Regulation of
COX-2 in Endothelial Cells
We next analyzed the effects of eNOS inhibition on COX-2
promoter activity in GM7372-EL cells, whose endoglin levels
were overinduced at the highest Dox concentration. L-NAME
selectively increased COX-2 promoter activity in endoglin-
induced cells (Figure 6A), suggesting that reduced NOS
activity was associated with increased COX-2 expression. By
contrast, treatment with the NO donor sodium nitroprusside
(SNP) decreased COX-2 promoter activity in both groups of
cells, indicating that NO inhibited COX-2 activity.
Figure 3. Western blot analysis of endoglin, COX-1, COX-2, and
tubulin in murine aortic endothelial cells and L6E9 myoblasts. A,
Extracts of Eng/ and Eng/ murine aortic endothelial cells. B,
Extracts of L6E9 myoblasts transfected with vector alone (Eng)
or with human L-endoglin (Eng). Densitometry results are
expressed as the relative ratio of COX-2 to -tubulin and repre-
sent the meansSEM of at least 3 paired experiments. *Signifi-
cant difference with control group (P0.05, Student t test).
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Western blot analysis also revealed that COX-2 expression
was selectively increased by L-NAME in endoglin overex-
pressing GM cells as compared with controls (Figure 6B).
The NO donor decreased COX-2 protein levels in untreated
GM cells but had no effect in endoglin overexpressing cells
(Figure 6B). L-NAME also increased COX-2 protein levels in
MAECs from Eng/, but not in those from Eng/ mice
(Figure 6C).
Induction of COX-2 Expression By TGF-1 Is Not
Affected By Endoglin
To test the possibility that TGF-1 is involved in endoglin-
dependent COX-2 expression, we assessed COX-2 levels in
myoblasts. TGF-1 induced a dose-dependent increase in
COX-2 expression in both mock and endoglin transfectants.
The basal level of COX-2 was higher in the mock- versus
endoglin-transfected cells, and both basal levels steadily
increased after stimulation with increasing concentrations of
TGF-1 (Figure 7A). The relative rise in COX-2 induced by
TGF-1 was similar (1.4- and 1.6-fold at 5 pM TGF-1; 2.1-
and 1.8-fold at 50 pM TGF-1), indicating that endoglin
affected basal levels, but not the TGF-1–mediated increase
in COX-2.
The potential involvement of endoglin in the TGF-–
induced COX-2 promoter transactivation was further tested
Figure 4. Relationship between endoglin and COX-2 in
GM7372-EL endothelial cells. A, Bovine endothelial GM7372-EL
cells were incubated with increasing concentrations of doxycyclin
(Dox) for 48 hours to induce endoglin expression. Endoglin, COX-2,
eNOS, and -tubulin were detected in total cell extracts by West-
ern blot analysis. Figure is representative of 3 separate experi-
ments. Densitometry results are expressed as % of maximal COX-
2/-tubulin and endoglin/-tubulin ratios (upper histogram) or % of
basal COX-2/-tubulin and eNOS/-tubulin ratios (lower histo-
gram). B, Bovine endothelial GM7372-EL cells were transfected
with the pXP2-COX-2 luc reporter vector and incubated with
increasing concentrations of Dox for 48 hours. COX-2 promoter
transactivity was measured using the luciferase reporter assay. The
data are representative of 3 separate experiments.
Figure 5. Differential COX-2 response of Eng/ and Eng /
mice to chronic treatment with L-NAME. Mice were treated with
or without L-NAME in their drinking water for 28 days. COX-2
expression in renal tissue (A) or lungs (B) is shown. The data are
expressed as meanSEM (n8) of the ratio COX-2/-tubulin
relative to the untreated Eng/ mice. *P0.05 vs Eng/ without
L-NAME; 2-way ANOVA and Scheffe´ test.
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by siRNA experiments in human endothelial cells. Transfec-
tion with pSUPER-endoEx4 vector encoding specific se-
quences of siRNA that suppress endoglin expression30 in-
creased the basal levels of COX-2 but did not alter the
stimulation by TGF-1 (2.5-fold versus 3.3-fold in the
control cells) (Figure 7B). Nevertheless, taking into account
the overall absolute values observed in Figure 7, it appears
that the COX-2 expression levels in response to TGF-1 are
maximal in the absence of endoglin and decrease in its
presence.
Hemodynamic Studies
Because we observed an increase in COX-2 expression in
tissues of Eng/ mice and a higher urinary excretion of
PGE2, we next assessed if these alterations modify vascular
function. Changes in MAP were measured in Eng/ and
Eng/ mice after selective COX-2 blockade with parecoxib.
A rapid (5 minutes), transient, and statistically significant
increase in blood pressure was observed only in Eng/ mice
(Figure 8A). As NO and COX products are both implicated in
maintenance of vascular resistance, we determined changes in
blood pressure in Eng/ and Eng/ mice after COX and
NOS blockade. Before inhibition of NO synthesis with
L-NAME further substantiated the effect of parecoxib on
Eng/ mice. A small but significant and sustained increase in
MAP was observed in Eng/ mice, but not in their littermate
controls (Figure 8B), and after 30 minutes no significant
differences in MAP were seen between the 2 groups of mice.
Administration of the NOS inhibitor L-NAME alone induced
Figure 6. Effect of NO levels on endoglin-dependent regulation of
COX-2 in endothelial cells. A, Bovine endothelial GM7372-EL cells
were incubated with doxycyclin (Dox) (500 ng/mL) for 24 hours to
induce endoglin, transfected with the pXP2-COX-2 luc reporter vector,
and incubated for 24 hours with L-NAME (5 mmol/L) or SNP
(100 mol/L), as indicated. Transactivation of the COX-2 promoter
was measured using the luciferase reporter assay. Data from 1 repre-
sentative experiment of 3 different ones in triplicates are shown. B,
The GM7372-EL cells were incubated with Dox for 24 hours, followed
by treatment with L-NAME (5 mmol/L) or SNP (100 mol/L) for 24
hours. COX-2 and -tubulin expression were measured by Western
blot; a representative gel and its relative COX-2/tubulin of 2 different
experiments is shown. C, Mouse aortic endothelial cells from Eng/
and Eng/ mice were treated with or without 10 mmol/L L-NAME for
24 hours, lysed, and COX-2 expression was assessed by Western
blot. Data from 6 different experiments are expressed respect to cells
without L-NAME (Arbitrary value1, for both untreated groups).
*P0.05 vs cells without L-NAME.
Figure 7. Induction of COX-2 by TGF-1. A, Mock- and
endoglin-transfected L6E9 myoblasts were plated at identical
density, grown for 24 hours, serum-starved for 24 hours, and
treated with increasing concentrations of active TGF-1 or con-
trol vehicle. Cellular extracts were analyzed by Western blot and
densitometry. Data from a representative experiment out of 2
different ones are shown. B, The human endothelial cell line
HMEC-1 was transiently transfected with the pXP2-COX-2 luc
reporter vector and pSUPER-Endo/Ex4, encoding an endoglin-
specific siRNA or pSUPER-C as negative control. After incuba-
tion for 36 hours, cells were incubated with TGF-1 for 24
hours. Transcriptional COX-2 activity was measured using the
luciferase reporter assay. An experiment representative of 3 dif-
ferent ones in triplicates is shown.
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a sustained hypertensive response in Eng/ animals
(45 mm Hg; Figure 8C), whereas almost no response was
observed in Eng/ mice (Figure 8D), as reported previous-
ly.14 To assess the effect of blocking NO synthesis in the
absence of COX-2–derived prostanoids, we administered
L-NAME to animals pretreated with parecoxib or indometh-
acin. COX-2 inhibition did not modify the effects of
L-NAME in Eng/ mice (Figure 8C). In contrast, both COX
inhibitors (parecoxib and indomethacin) led to a significant
increase in the pressor effect of L-NAME in Eng/ mice
(Figure 8D).
Discussion
The present study demonstrates that COX-2 was overex-
pressed in several tissues of Eng/ mice relative to Eng/
littermates. This increased COX-2 expression was mainly
observed in the vascular endothelium and was not accompa-
nied by changes in COX-1 expression. This finding was
supported by the observation that cultured aortic endothelial
cells from Eng/ mice expressed higher COX-2 but similar
COX-1 levels when compared with cells from Eng/ mice.
The inverse correlation between endoglin and COX-2 levels
was also seen in the L6E9 rat myoblast cell line, which
showed reduced COX-2 expression when transfected with
endoglin. Also, in the bovine endothelial GM7372-EL line,
Dox-inducible endoglin expression was inversely correlated
with COX-2 promoter activity and protein levels.
An additional proof of increased COX-2 activity in the
Eng/ mice is their higher urinary excretion of PGE2, a major
product of COX-initiated arachidonic acid metabolism in the
kidney.31 Because we did not observe differences in renal
COX-1 expression between Eng/ and Eng/ mice but
increased renal COX-2 expression in Eng/ mice, we suggest
that the increased urinary excretion of PGE2 is mainly caused
by increased COX-2 metabolism.
The increase in COX-2 expression in tissues and the higher
urinary excretion of PGE2 in Eng/ mice led to measure-
ments of arterial pressure in Eng/ and Eng/ mice after
COX-2 blockade. The selective inhibitor parecoxib induced a
transient blood pressure increase only in Eng/ mice, which
have higher levels of COX-2. Because this enzyme generates
predominantly vasodilators,32 the rise in pressure on its
inhibition suggests a more significant role for COX-2 in the
vasoregulation of Eng/ than in Eng/ mice. As we previ-
ously showed that eNOS expression and activity was lower in
these mice14,15 and that their hypertensive response to
L-NAME was reduced, we measured the effects of combined
inhibition of both NOS and COX activities. Pretreatment of
Eng/ mice with parecoxib did not enhance the increase in
MAP induced by L-NAME. In contrast, the same treatment
applied to Eng/ mice restored the hypertensive response to
L-NAME, suggesting that COX-2–derived vasodilators con-
tribute substantially to MAP regulation in Eng/ mice.
Furthermore, depletion of NO by pretreatment with L-NAME
followed by selective COX-2 inhibition induced an increase
Figure 8. Effect of COX or NO synthesis inhibition on MAP. A, Effect of the COX-2 inhibitor parecoxib on MAP in Eng/ and Eng/
mice. *P0.05 vs basal value; #P0.05 vs Eng/ mice. B, Effect of the COX-2 inhibitor parecoxib on MAP in Eng/ and Eng/ mice
pretreated with L-NAME. Parecoxib is administered at time 0. *P0.05 vs time 0 value; #P0.05 vs Eng/ group. C, Effect of L-NAME
on MAP in Eng/ mice when given alone or after pretreatment with indomethacin (Indo) or parecoxib (Parec). L-NAME is administered
at time 0. *P0.05 vs time 0 value. D, Effect of L-NAME on MAP in Eng/ mice when given alone or after pretreatment with indometh-
acin or parecoxib. L-NAME is administered at time 0. *P0.05 vs time 0 value; #P0.05 vs Eng/ group treated only with L-NAME (‚).
Analysis by 2-way ANOVA and Scheffe´ test in all panels.
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in MAP only in Eng/ mice. These findings suggest a critical
role for COX-2 derivatives in the vasoregulation of Eng/
mice, which may compensate for the decreased NO
availability.
To investigate the specific mechanism responsible for
increased COX-2 expression in Eng/ mice, we postulated
that decreased NO production in Eng/ mice,14,15 could
stimulate COX-2 expression. Our results corroborate this
hypothesis, showing that chronic inhibition of NOS activity
in Eng/ mice leads to a significant increase in COX-2
expression and PGE2 urinary excretion. However, L-NAME
had no effect on the already elevated COX-2 found in Eng/
mice. These findings suggest that chronically decreased NO
synthesis in Eng/ mice might have led to a maximal
increase in COX-2 and represents a mechanism of physio-
logical adaptation to endoglin haploinsufficiency.
Because endoglin is a coreceptor for TGF-, it was of
interest to measure the effects of this cytokine on COX-2
expression in cells expressing either no or high endoglin.
COX-2 can be stimulated by TGF-1 in several tissues and
cell types,33–35 and endoglin can neutralize some cellular
effects of TGF-1.27,36,37 Our experiments with cultured cells
demonstrated that although TGF-1 increased COX-2 ex-
pression, the level of induction was not different in mock- and
endoglin-transfected myoblasts, despite higher basal levels in
endoglin negative cells. Additionally, suppression of endog-
lin expression in human endothelial cells resulted in increased
basal levels in COX-2 promoter activity but did not lead to
further induction by TGF-1. These results suggest that
endoglin regulates total levels of COX-2 in basal and TGF-
1–treated cells, but does not alter the TGF-1–dependent
induction of COX-2 expression.
In conclusion, our results demonstrate upregulation of
endothelial COX-2 and a consequent increase in vasodilator
prostaglandin production in a mouse model of HHT1. The
inverse correlation between endoglin and COX-2 expression
was confirmed in endothelial and nonendothelial cells and
suggests that endoglin modulates COX-2 expression. Our
results also indicate that decreased eNOS activity, likely via
reduction of NO production, might mediate the rise in
COX-2.
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Materials and Methods 
Mice 
Generation and genotyping of Eng+/– and littermate control mice (on a C57BL/6 background) 
was previously described.1  Mice were kept in ventilated rooms, in a germ-free facility. All 
studies were performed in parallel in Eng+/– and littermate Eng+/+ female mice of 4-6 months of 
age (20-25 g). Mice were treated in accordance with international and national guidelines for 
the care and use of laboratory animals, as issued by Conseil de l´Europe (Official Daily N. 
L358/1-358/6, 18th December 1986), Spanish Government (Boletín Oficial del Estado N. 67, 
pp. 85098512, 18th March 1988, and Boletín Oficial del Estado N. 256, pp. 3134931362, 28th 
October 1990), and the U.S. National Institutes of Health (Guide for the Care and Use of 
Laboratory Animals, NIH publication no. 8523). All animal procedures performed were 
approved by the University of Salamanca Animal Care and Use Committee.  
Blood pressure measurements 
Arterial blood pressure has been measured in anesthetized mice as previously described.2,3 
Mice were anaesthetized with sodium pentobarbital (40 mg/kg b. w., i.p.), body temperature 
was maintained at 37ºC using a heating pad, and tracheotomy was performed. The right carotid 
artery was cannulated with PE-10 and PE-50 tubings and connected to a pressure transducer for 
continuous measurement of arterial blood pressure. Arterial pressure was recorded in a digital 
data recorder (MacLab/4e, AD Instruments, Australia) and analyzed using Chart v 3.4 (an 
application program). The left jugular vein was catheterized for the administration of 
vasoactive substances. Supplemental doses of anesthesia (10 mg sodium pentobarbital/kg b. 
wt.) were administrated as required. If anesthetic addition caused any detectable change in 
arterial pressure or heart rate, the animals were discarded. 
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Changes in mean arterial pressure (MAP) in response to vasoactive substances were measured 
in Eng+/– and Eng+/+ mice as described.14  Mice were pretreated with the non-selective 
cyclooxygenase inhibitor indomethacin (Sigma, I-7378; 5 mg/kg b.m., s.c.) for 1 hour, the 
selective COX 2 inhibitor parecoxib (Dynastat, Pharmacia EEIG, Buckinghamshire, U.K; 40 
mg/kg b.m., i.v.) for 30 min., or the NO synthesis inhibitor L-NAME (50 mg/kg b.m., i.v.) for 
1 hour. The reason for the pre-treatment duration of each inhibitor is to allow the time 
necessary to obtain a stable MAP. Subsequent combined treatments were given as indicated. 
Animals showing any sign of hemorrhage and animals with a systolic blood pressure lower 
than 60 mmHg were excluded. 
Tissue and aortic endothelial cells preparation. 
Mice were deeply anesthetized using isoflurane (Forane, Abbott Lab). The kidneys, lungs and 
femoral arteries were removed, frozen in liquid nitrogen, individually ground into a fine 
powder and stored at –80ºC until used for protein and total RNA extraction. Mouse aortic 
endothelial cells (MAEC) from Eng+/+ and Eng+/− mice were isolated and cultured as 
previously described.2 In all experiments, cells did not exceed passage 3, and were 
characterized using antibodies to von Willebrand factor and CD31/PECAM-1. In each 
experiment, a pool of cells from three different aortas was used to decrease inter-individual 
variation. 
Chronic nitric oxide synthase inhibition 
To inhibit NO synthesis in vivo, L-NAME was administered at a dose of 10 mg/kg/day in the 
drinking water during 28 days, based on an average water intake of 4-5ml per mouse per day. 
For the last two days of L-NAME administration, mice were transferred to metabolic cages for 
urine collection. The efficiency of NO synthesis inhibition was assessed by measuring plasma 
and urine nitrite levels as described.32 
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PGE2, creatinine and nitrite detection 
Urine was transferred to eppendorf tubes containing indomethacin (10 µg/mL), centrifuged and 
stored at -40°C. PGE2 was measured using a high sensitivity immunoassay (R&D Systems) and 
creatinine was quantified colorimetrically using a modified Jaffe´s method. Plasma and urine 
concentrations of nitrites were determined by a modification of the Griess method as 
described.3  
Immunohistochemistry 
Immunostaining was performed on buffered formalin fixed, paraffin-embedded tissues, 
following antigen retrieval with a citrate solution (BioGenex) in a microwave oven for 10 
minutes. Endogenous peroxidase was blocked by incubation in 3% H2O2 and the sections were 
incubated with an affinity purified polyclonal antibody to COX-2 (Santa Cruz Biotechnology; 
catalogue # sc-1747) and processed using the goat ABC Staining system (Santa Cruz 
Biotechnology; catalogue # sc-2023) combined with the chromogen diaminobenzidine (DAB, 
BioGenex). Negative controls were prepared using a non-immune serum. Sections were 
counterstained with hematoxylin-eosin.  
Cell transfectants expressing endoglin and endothelial cell lines 
The rat myoblast cell line L6E9, and the tetracycline-inducible bovine endothelial GM7372-EL 
cell line4 were cultured in DMEM, while the human microvascular endothelial HMEC-1 cells5 
were grown in EMB (Gibco). Generation of doxycyclin-inducible endoglin-expressing 
GM7372-EL cells and of stable rat myoblast transfectants expressing human L-endoglin was 
previously described.4,6 The myoblast transfectants were cultured in the presence of 400 µg/ml 
of the G418 antibiotic. GM7372-EL cells, plated at 5 x 105/dish in 60-mm culture plates, were 
incubated with or without Dox for 24 hours and treated or not with L-NAME (5mM) or SNP 
(100µΜ) for 24 hours prior to Western blot analysis. To analyze the effect of TGF-β1 on 
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COX-2 expression, L6E9 myoblast were incubated with different concentrations of 
recombinant human TGF-β1 (0-500 pM) for 24 hours prior to immunodetection analysis. 
Western blot analysis  
Preparation of tissue and cell extracts for Western blot analysis was previously described. 2,7 
COX-1 and COX-2 expression was assessed using a mouse monoclonal anti-COX-1 and a goat 
polyclonal anti COX-2 (Santa Cruz Biotechnology). Human endothelial (Transduction 
Laboratories) and RAW 264.7 phorbol ester activated (Santa Cruz Biotechnology) cell lysates 
were used as positive controls for COX-1 (70-72kDa) and COX-2 (74kDa), respectively. 
Murine and human endoglin were detected using the rat monoclonal antibody MJ7/18 8 or the 
mouse monoclonal antibody P4A4,9 respectively. eNOS was detected with a rabbit polyclonal 
anti-endothelial type constitutive NOS (Santa Cruz Biotechnology ; catalogue # sc-653). 
Specific protein levels were normalized to either α-tubulin or β-tubulin levels as indicated. 
Northern blot Analysis 
Total RNA was isolated from lungs and kidneys using the guanidinium thiocyanate-phenol-
chloroform method, as previously described.2 A 4.5-kb fragment of mouse COX-2 cDNA in 
pcDNA I/neo (kindly given by Dr. Santiago Lamas, Centro Nacional de Investigaciones 
Cardiovasculares, Madrid, Spain) was used as probe. The 28S ribosomal subunit probe (0.7-
kb) served as an internal control. 
Reporter assays 
COX-2 transcriptional activity was measured using a pXP2LUC reporter plasmid containing 
the –1795 to +104 region of the human COX-2 promoter.10 When necessary, cells incubated 
for 24 hours with L-NAME (5mM) or SNP (sodium nitroprussiate; 100µM). Transactivation 
was measured using the luciferase reporter assay. All transient transfections were carried out 
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using Superfect (Qiagen). Relative luciferase units (RLU) were determined in a TD20/20 
luminometer (Promega). Samples were co-transfected with the SV40-ß-galactosidase 
expression plasmid to correct for transfection efficiency. ß-galactosidase activity was measured 
using the Galacto-Light kit (Tropix). Experiments were performed in triplicate, at least three 
times; representative ones are illustrated. 
RNA interference studies 
The pSUPER-Endo-Ex4 vector was generated by inserting a double-stranded oligonucleotide 
corresponding to human endoglin exon 4 into pSUPER plasmid.11 Upon transfection, the 
pSUPER-Endo-Ex4 generates intracellular expression of small endoglin RNA molecules that 
silence the human endoglin gene. The pSUPER-C vector containing an endoglin-unrelated 
sequence was used as a negative control.11 To suppress the expression of endoglin, HMEC-1 
cells were transfected with pSUPER plasmids 36 hours prior to functional analysis. After 
incubation for 36 hours, 400 pM TGF-β1 was added and the cells were incubated for 24 hours. 
COX-2 transcriptional activity was measured using the luciferase reporter assay. 
Statistics 
Data are expressed as mean ± SEM. Significance was tested using Student´s t test when two 
groups are compared, and 2-way repeated-measures ANOVA followed by Scheffe´s test for 
multiple intra- and inter-group comparisons. P <0.05 was considered significant.  
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Figure Legend 
Online Figure 1. Expression of COX-1 and COX-2 in femoral arteries of Eng+/+ and Eng+/– 
mice. A, Representative Western blot analysis of renal tissues with antibodies specific for 
COX-1, COX-2, or β-tubulin (loading control). B, Densitometry results are expressed as 
COX/tubulin ratios. Data shown are mean ± SEM of 8 mice per group. *P < 0.05 vs. Eng+/+ 
group (Student´s t test).  
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